Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase 1/2 study of oral larotrectinib in advanced solid tumors or primary CNS tumors with NTRK fusion
MOH_2020-02-13_007353Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of larotrectinib in Nonhematologic neoplasms, central nervous system tumor, congenital fibrosarcoma (CFS) and 2 more, sponsored by Bayer. Primary endpoints: Safety and dose evaluation and Magnitude and duration of response. Started Dec 2018; status: completed.
02
Drugs
larotrectinib
03
Conditions
Nonhematologic neoplasmscentral nervous system tumorcongenital fibrosarcoma (CFS)mesoblastic nephroma (CMN)secretory breast carcinoma (SBC)
Beyond the preview
Go deeper on MOH_2020-02-13_007353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-02-13_007353.